18698-59-4 Usage
Description
(2-acetoxy-benzoic acid)-acetic acid-anhydride, commonly known as aspirin, is a chemical compound that serves as a widely recognized pain reliever and anti-inflammatory medication. It is a combination of acetylsalicylic acid (ASA) and acetic acid anhydride, which together create a stable and easily soluble form of the drug. Aspirin works by inhibiting the production of prostaglandins, chemicals responsible for causing pain, fever, and inflammation in the body.
Uses
Used in Pharmaceutical Industry:
(2-acetoxy-benzoic acid)-acetic acid-anhydride is used as a pain reliever and anti-inflammatory agent for the treatment of various conditions such as headaches, muscle aches, fever, and arthritis. Its ability to inhibit prostaglandin production makes it an effective medication for managing pain and reducing inflammation.
Used in Healthcare:
(2-acetoxy-benzoic acid)-acetic acid-anhydride is used as a fever reducer, helping to lower body temperature in cases of fever caused by illness or infection. This property makes it a valuable tool in healthcare for managing fever and associated discomfort.
It is important to use (2-acetoxy-benzoic acid)-acetic acid-anhydride as directed by a healthcare professional to avoid potential side effects and complications.
Check Digit Verification of cas no
The CAS Registry Mumber 18698-59-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,6,9 and 8 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 18698-59:
(7*1)+(6*8)+(5*6)+(4*9)+(3*8)+(2*5)+(1*9)=164
164 % 10 = 4
So 18698-59-4 is a valid CAS Registry Number.
18698-59-4Relevant articles and documents
The synthesis of non-steroidal anti-inflammatory drug (NSAID)-lantadene prodrugs as novel lung adenocarcinoma inhibitors via the inhibition of cyclooxygenase-2 (COX-2), cyclin D1 and TNF-α-induced NF-κB activation
Suthar, Sharad Kumar,Lee, Hong Boon,Sharma, Manu
, p. 19283 - 19293 (2014/05/20)
The ester conjugates of potent nuclear factor-kappa B (NF-κB) inhibitors with cyclooxygenase (COX) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) present a novel approach towards cancer treatment. The ester prodrugs of pentacyclic triterpenoid 3β,22β-dihydroxy-olean-12-en-28- oic acid (4) with different NSAIDs were synthesized for the dual inhibition of NF-κB and COX-2. The results indicated that the lead compound 14 suppressed the tumor necrosis factor-alpha-induced (TNF-α-induced) activation of NF-κB by inhibiting the inhibitor of the nuclear factor-kappa B kinase (IKK) activation, the inhibitor of the nuclear factor-kappa B alpha (IκBα) degradation and at the same time, it down-regulated the NF-κB mediated protein expression of COX-2 and cyclin D1. Furthermore, compound 14 inhibited lung adenocarcinoma A549 cell proliferation in a dose dependent manner and was found to be 50 folds more active than cisplatin in terms of IC50. Compound 14 was also found to be stable in an acidic pH, while it hydrolyzed readily in human plasma to release the active promoieties. From the results it can be inferred that the lantadene-NSAID prodrugs are promising anticancer candidates against lung cancer with a dual inhibition capability against both NF-κB and COX-2. the Partner Organisations 2014.
